Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 925,602
  • Shares Outstanding, K 40,490
  • Annual Sales, $ 726,410 K
  • Annual Income, $ 7,030 K
  • EBIT $ 76 M
  • EBITDA $ 166 M
  • 60-Month Beta 0.21
  • Price/Sales 1.23
  • Price/Cash Flow 5.73
  • Price/Book 1.37

Options Overview Details

View History
  • Implied Volatility 74.96% (-0.36%)
  • Historical Volatility 34.76%
  • IV Percentile 79%
  • IV Rank 44.49%
  • IV High 119.80% on 10/30/25
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 15) 3.32 (14.52%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 1,133
  • Open Int (30-Day) 1,183
  • Expected Range 19.52 to 26.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.46
  • Number of Estimates 2
  • High Estimate 0.46
  • Low Estimate 0.45
  • Prior Year 0.39
  • Growth Rate Est. (year over year) +17.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.43 +11.45%
on 02/06/26
23.73 -4.02%
on 02/26/26
+2.41 (+11.86%)
since 02/05/26
3-Month
18.80 +21.14%
on 01/20/26
27.16 -16.14%
on 12/16/25
-1.22 (-5.06%)
since 12/05/25
52-Week
18.80 +21.14%
on 01/20/26
27.64 -17.60%
on 09/03/25
-0.74 (-3.13%)
since 03/05/25

Most Recent Stories

More News
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference

BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 22.80 (-0.26%)
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data...

PCRX : 22.80 (-0.26%)
Pacira: Q4 Earnings Snapshot

Pacira: Q4 Earnings Snapshot

PCRX : 22.80 (-0.26%)
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif.,...

PCRX : 22.80 (-0.26%)
Pacira to Report 2025 Financial Results on Thursday February 26, 2026

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 22.80 (-0.26%)
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted...

PCRX : 22.80 (-0.26%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 22.80 (-0.26%)
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry...

PCRX : 22.80 (-0.26%)
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

-- LG Chem becomes exclusive distributor of EXPAREL --  – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 ...

PCRX : 22.80 (-0.26%)
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,...

PCRX : 22.80 (-0.26%)

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 24.40
2nd Resistance Point 23.69
1st Resistance Point 23.28
Last Price 22.80
1st Support Level 22.16
2nd Support Level 21.45
3rd Support Level 21.04

See More

52-Week High 27.64
Fibonacci 61.8% 24.26
Fibonacci 50% 23.22
Last Price 22.80
Fibonacci 38.2% 22.18
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar